Jordyn Hofer
Family · Sioux Falls, SDNPI 1114698875
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$590
- Novo Nordisk$491
- Pfizer$367
- Lilly USA, LLC$315
- Amgen$202
- Astellas Pharma US Inc$149
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $590 |
| Novo Nordisk | 37 | $491 |
| Pfizer | 30 | $367 |
| Lilly USA, LLC | 22 | $315 |
| Amgen | 13 | $202 |
| Astellas Pharma US Inc | 10 | $149 |
| Daiichi Sankyo Inc. | 8 | $135 |
| GSK | 8 | $116 |
| Mylan Specialty L.p. | 7 | $114 |
| AstraZeneca | 5 | $74 |
| Merck | 5 | $70 |
| Johnson & Johnson | 5 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Boehringer Ingelheim | 4 | $59 |
| Bayer | 3 | $56 |
| Novartis | 2 | $52 |
| Viatris Specialty LLC | 2 | $47 |
| Grifols USA, LLC | 2 | $46 |
| Exact Sciences | 3 | $45 |
| Dexcom, Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 3 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Dynavax Technologies Corporation | 2 | $33 |
| Radius Health, Inc. | 1 | $31 |
| Boston Scientific | 2 | $31 |
| Abbott | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Organon | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
How this compares
$3,455 in reported general payments places this provider in the 95th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $27,502 |
| TrulicityDulaglutide | 15 | $20,285 |
| MounjaroTirzepatide | 16 | $18,615 |
| XareltoRivaroxaban | 14 | $17,172 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,210 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $11,966 |
| FarxigaDapagliflozin Propanediol | 14 | $10,916 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,807 |
| Rosuvastatin Calcium | 93 | $2,239 |
| Tizanidine Hcl | 14 | $1,858 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,442 |
| Metoprolol Succinate | 63 | $1,145 |
| Atorvastatin Calcium | 124 | $1,127 |
| Omeprazole | 129 | $1,089 |
| Gabapentin | 58 | $952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $315 | $38,89931 claims |
| Novo NordiskOzempic | $491 | $27,50220 claims |
| Johnson & JohnsonXarelto | $67 | $17,17214 claims |
| GSKTrelegy Ellipta | $116 | $13,21017 claims |
| Boehringer IngelheimGlyxambi | $59 | $11,96621 claims |
| AstraZenecaFarxiga | $74 | $10,91614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family providers in South Dakota.
Other family in Sioux Falls
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Michelle VanhoveSioux Falls$7K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Megan MoedingSioux Falls$5K
- Kari WestenkirchnerSioux Falls$4K
- Brooke MunkSioux Falls$4K
- Rebekka KlemmeSioux Falls$4K
- Jennifer RedmondSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.